Akoustis Technologies Inc (AKTS)

$0.04 0.00 (-9.05%)
Market Cap 5.75M
Revenue (ttm) 27.38M
Net Income (ttm) -167.95M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -613.40%
Debt to Equity Ratio 0.00
Volume 118,703,398
Avg Vol 26,170,799
Day's Range N/A - N/A
Shares Out 154.59M
Stochastic %K 6%
Beta 1.91
Analysts Sell
Price Target $1.00

Company Profile

Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervi...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 461 4023
Address:
17 Drydock Avenue, Suite 17-401, Boston, United States
STACKD0E
STACKD0E Jun. 30 at 10:37 PM
$CRBU $AKTS 🙃✨️
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 30 at 9:22 PM
Aktis on Fire $AKTS $RADX $SLS
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:07 PM
$AKTS
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:07 PM
$AKTS is anyone in as low as I am?
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:05 PM
$AKTS all I hear is crickets? You people are a bunch of HATERS.! Nobody give me my props?
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:02 PM
$AKTS hit that follow button
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:01 PM
$AKTS How did I get a ton of shares, practically for free? I married the daughter of the CEO? And as a present, given me this.
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 30 at 3:41 PM
Fair Analysis between $AKTS at $1.815 billion market cap vs peer $RADX 15% Equity holder $LNTH is invested in Radiopharm Theranostics and there’s a potential deal for LNTH to be acquired for $7 billion plus by PE backed Curium. https://chatgpt.com/s/m_6a43e32bcf5c8191a9e1f061389c43c1
1 · Reply
CaesarZane
CaesarZane Jun. 29 at 9:52 PM
$PAYP $JAN $AKTS 📈📈📈 https://youtu.be/60T_XouDMok
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 26 at 7:31 PM
$AKTS 🛑do you think I care it’s down a little bit today? I was given a ton of free shares because I married the daughter of the CEO. My bus you people if you are attractive like I am a perfect 10 go to a nice bar and find a nice professional woman. Who knows maybe you can strike gold like I have.🤷
1 · Reply
Latest News on AKTS
Aktis Oncology initiated with a Strong Buy at Raymond James

2026-06-15T20:12:10.000Z - 19 days ago

Aktis Oncology initiated with a Strong Buy at Raymond James

Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 4:20 PM EDT - 4 weeks ago

Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026

Aktis Oncology Slides: FY 2026

Jun 3, 2026, 4:20 PM EDT - 4 weeks ago

Aktis Oncology Slides: FY 2026

Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright

2026-06-02T16:28:44.000Z - 4 weeks ago

Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

May 27, 2026, 4:05 PM EDT - 5 weeks ago

Aktis Oncology to Present at the Jefferies Global Healthcare Conference

Aktis Oncology Transcript: Status update

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Aktis Oncology Transcript: Status update

Aktis Oncology Slides: Status update

May 27, 2026, 8:00 AM EDT - 5 weeks ago

Aktis Oncology Slides: Status update

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

May 21, 2026, 5:21 PM EDT - 6 weeks ago

Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors

Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 1:00 PM EDT - 7 weeks ago

Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026

Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M

2026-05-11T21:36:58.000Z - 7 weeks ago

Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

May 11, 2026, 4:01 PM EDT - 7 weeks ago

Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026

Aktis Oncology Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Aktis Oncology Earnings release: Q1 2026

Aktis Oncology Quarterly report: Q1 2026

May 11, 2026, 4:00 PM EDT - 7 weeks ago

Aktis Oncology Quarterly report: Q1 2026

Aktis Oncology to Present at the BofA Securities Health Care Conference

May 6, 2026, 8:00 AM EDT - 2 months ago

Aktis Oncology to Present at the BofA Securities Health Care Conference

Aktis Oncology Transcript: Study update

May 5, 2026, 8:00 AM EDT - 2 months ago

Aktis Oncology Transcript: Study update

Aktis Oncology Press release: Study update

May 5, 2026, 8:00 AM EDT - 2 months ago

Aktis Oncology Press release: Study update

Aktis Oncology Slides: Study update

May 5, 2026, 8:00 AM EDT - 2 months ago

Aktis Oncology Slides: Study update

Aktis Oncology initiates clinical trial of AKY-25191

2026-05-04T21:11:48.000Z - 2 months ago

Aktis Oncology initiates clinical trial of AKY-25191

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

May 4, 2026, 4:05 PM EDT - 2 months ago

Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Aktis Oncology initiated with an Outperform at William Blair

2026-04-29T10:50:44.000Z - 2 months ago

Aktis Oncology initiated with an Outperform at William Blair

Aktis Oncology appoints Gormley as independent director of Board of Directors

2026-04-16T14:16:14.000Z - 2 months ago

Aktis Oncology appoints Gormley as independent director of Board of Directors

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Apr 16, 2026, 8:00 AM EDT - 2 months ago

Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors

Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright

2026-03-31T10:31:00.000Z - 3 months ago

Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright

Aktis Oncology announces FDA clearance of AKY-25191 trial

2026-03-30T20:17:16.000Z - 3 months ago

Aktis Oncology announces FDA clearance of AKY-25191 trial

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Mar 30, 2026, 4:01 PM EDT - 3 months ago

Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results

Aktis Oncology Earnings release: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Aktis Oncology Earnings release: Q4 2025

Aktis Oncology Annual report: Q4 2025

Mar 30, 2026, 8:00 AM EDT - 3 months ago

Aktis Oncology Annual report: Q4 2025

Aktis Oncology Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 1:40 PM EDT - 4 months ago

Aktis Oncology Transcript: Leerink Global Healthcare Conference 2026

Aktis Oncology initiated with a Buy at H.C. Wainwright

2026-03-09T10:21:33.000Z - 4 months ago

Aktis Oncology initiated with a Buy at H.C. Wainwright

Aktis Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 4 months ago

Aktis Oncology Transcript: TD Cowen 46th Annual Health Care Conference

Aktis Oncology Slides: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:10 PM EST - 4 months ago

Aktis Oncology Slides: TD Cowen 46th Annual Health Care Conference

Aktis Oncology to Present at Upcoming March Investor Conferences

Feb 24, 2026, 4:05 PM EST - 4 months ago

Aktis Oncology to Present at Upcoming March Investor Conferences

Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

2026-02-24T13:12:13.000Z - 4 months ago

Aktis Oncology receives U.S. FDA Fast Track Designation for AKY-1189

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Feb 24, 2026, 8:00 AM EST - 4 months ago

Aktis Oncology Receives U.S. FDA Fast Track Designation for AKY-1189, a Nectin-4 Miniprotein Radioconjugate

Aktis Oncology initiated with an Outperform at Leerink

2026-02-03T11:30:36.000Z - 5 months ago

Aktis Oncology initiated with an Outperform at Leerink

Aktis Oncology initiated with a Buy at BofA

2026-02-03T11:25:45.000Z - 5 months ago

Aktis Oncology initiated with a Buy at BofA

Aktis Oncology initiated with a Buy at TD Cowen

2026-02-03T10:40:19.000Z - 5 months ago

Aktis Oncology initiated with a Buy at TD Cowen

Aktis Oncology initiated with an Overweight at JPMorgan

2026-02-03T10:00:20.000Z - 5 months ago

Aktis Oncology initiated with an Overweight at JPMorgan

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 13, 2026, 6:30 AM EST - 6 months ago

Aktis Oncology Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO

2026-01-12T16:15:19.000Z - 6 months ago

Opening Day: Aktis Oncology raises $318M in 2026’s first biotech IPO

ANDG BUDA FJET MDLN

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

Jan 9, 2026, 12:58 PM EST - 6 months ago

Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets

LLY

Aktis Oncology prices upsized US IPO at $18 per share

Jan 8, 2026, 9:20 PM EST - 6 months ago

Aktis Oncology prices upsized US IPO at $18 per share

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Jan 8, 2026, 8:48 PM EST - 6 months ago

Aktis Oncology Announces Pricing of its Upsized Initial Public Offering

Aktis Oncology Registration statement: Registration Filing

Jan 7, 2026, 7:00 AM EST - 6 months ago

Aktis Oncology Registration statement: Registration Filing

Aktis Oncology Registration statement: Registration Filing

Jan 5, 2026, 7:00 AM EST - 6 months ago

Aktis Oncology Registration statement: Registration Filing

Aktis Oncology files for US IPO as biotech listings rebound

Dec 19, 2025, 5:51 PM EST - 7 months ago

Aktis Oncology files for US IPO as biotech listings rebound

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Dec 19, 2025, 5:51 PM EST - 7 months ago

Phase 1 solid tumor biotech Aktis Oncology files for a $100 million IPO

Aktis Oncology IPO Registration Document (S-1)

Dec 19, 2025, 4:02 PM EST - 7 months ago

Aktis Oncology IPO Registration Document (S-1)

Aktis Oncology Registration statement: Registration Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

Aktis Oncology Registration statement: Registration Filing

Akoustis to pursue sale through chapter 11 process

2024-12-16T10:30:55.000Z - 1 year ago

Akoustis to pursue sale through chapter 11 process

QRVO

STACKD0E
STACKD0E Jun. 30 at 10:37 PM
$CRBU $AKTS 🙃✨️
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 30 at 9:22 PM
Aktis on Fire $AKTS $RADX $SLS
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:07 PM
$AKTS
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:07 PM
$AKTS is anyone in as low as I am?
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:05 PM
$AKTS all I hear is crickets? You people are a bunch of HATERS.! Nobody give me my props?
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:02 PM
$AKTS hit that follow button
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 30 at 4:01 PM
$AKTS How did I get a ton of shares, practically for free? I married the daughter of the CEO? And as a present, given me this.
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 30 at 3:41 PM
Fair Analysis between $AKTS at $1.815 billion market cap vs peer $RADX 15% Equity holder $LNTH is invested in Radiopharm Theranostics and there’s a potential deal for LNTH to be acquired for $7 billion plus by PE backed Curium. https://chatgpt.com/s/m_6a43e32bcf5c8191a9e1f061389c43c1
1 · Reply
CaesarZane
CaesarZane Jun. 29 at 9:52 PM
$PAYP $JAN $AKTS 📈📈📈 https://youtu.be/60T_XouDMok
0 · Reply
ResearchTrends09
ResearchTrends09 Jun. 26 at 7:31 PM
$AKTS 🛑do you think I care it’s down a little bit today? I was given a ton of free shares because I married the daughter of the CEO. My bus you people if you are attractive like I am a perfect 10 go to a nice bar and find a nice professional woman. Who knows maybe you can strike gold like I have.🤷
1 · Reply
RadioIsotope25
RadioIsotope25 Jun. 26 at 3:38 PM
$RADX $AKTS
0 · Reply
RadioIsotope25
RadioIsotope25 Jun. 25 at 10:41 PM
$RADX AKTS at $31 this week. Jumped $11 Makes RADX look insanely cheap https://stocks.apple.com/A_lNY8zIFQLy4KJfOGIvxMA $AKTS
2 · Reply
Aromadz
Aromadz Jun. 25 at 5:48 PM
$AKTS It looks like it got included in s&p global broad market index on late June, which coincides with its rise.
0 · Reply
jrodpikap
jrodpikap Jun. 25 at 1:38 PM
$AKTS what is going on with this Stock? No chatter what so ever on the boards and it’s up like 50% in the last few weeks.
0 · Reply
john565
john565 Jun. 24 at 4:48 PM
$AKTS Why up today?
1 · Reply
twitofstock
twitofstock Jun. 23 at 3:01 PM
$AKTS what/who is behind this pump ?
0 · Reply
StJohn_TudorJones
StJohn_TudorJones Jun. 18 at 10:39 PM
$TLX looking very promising recently (CMC/FDA overhangs continue to clear, validated by strong accumulation volume) — $AKTS & overall radiopharma equity momentum is strong too $RADX all of this portends well for RADX share-price action if/once RAD101 final Ph2b data hits (to be released any day now) and especially if it coincides with or is followed by a shareholder-friendly RAD101 deal
0 · Reply
jucebot
jucebot Jun. 18 at 1:35 PM
JUCE started a long in $MRVU @ $250.61 $AKTS $NOWL
2 · Reply
jucebot
jucebot Jun. 18 at 1:35 PM
JUCE grabbed a long position in $NOWL @ $4.17 $AKTS
0 · Reply
jucebot
jucebot Jun. 18 at 1:00 PM
JUCE just opened a long in $RUM @ $8.70 $AKTS
0 · Reply
jucebot
jucebot Jun. 18 at 1:00 PM
JUCE loaded up a long in $VRTL @ $155.77 $AKTS
0 · Reply
jucebot
jucebot Jun. 17 at 9:20 PM
JUCE grabbed a long position in $NVD @ $5.01 $AKTS $CRE $EZGO $FRMI
1 · Reply